| | | | By order of the Board of Directors, | |
| | | |
![]() |
|
| | | |
Thomas Gad
Founder, President, Interim Chief Executive Officer and Head of Business Development and Strategy |
|
| | | | | 1 | | | |
| | | | | 9 | | | |
| | | | | 9 | | | |
| | | | | 12 | | | |
| | | | | 16 | | | |
| | | | | 22 | | | |
| | | | | 22 | | | |
| | | | | 23 | | | |
| | | | | 28 | | | |
| | | | | 29 | | | |
| | | | | 32 | | | |
| | | | | 33 | | | |
| | | | | 34 | | | |
| | | | | 35 | | | |
| | | | | 37 | | | |
| | | | | 39 | | | |
| | | | | 39 | | | |
| | | | | 40 | | | |
| | | | | 40 | | | |
| | | | | 41 | | | |
| | | | | 41 | | | |
| | | | | 41 | | | |
| | | | | 44 | | | |
| | | | | 44 | | | |
| | | | | 45 | | | |
| | | | | 45 | | | |
| | | | | 46 | | | |
| | | | | 46 | | | |
| | | | | 46 | | | |
| | | | | 48 | | | |
| | | | | 49 | | | |
| | | | | 49 | | | |
| | | | | 51 | | | |
| | | | | 51 | | | |
| | | | | 52 | | | |
| | | | | 52 | | | |
| | | | | 52 | | | |
| | | | | 52 | | | |
| | | | | 52 | | |
| | | | By order of the Board of Directors, | |
| | | |
![]() |
|
| | | |
Thomas Gad
Founder, President, Interim Chief Executive Officer and Head of Business Development and Strategy New York, New York April 29, 2022 |
|
Name
|
| |
Age
|
| |
Position
|
|
Class I Directors and Nominees | | | | | | | |
Gérard Ber, Ph.D.(2)
|
| | 64 | | | Director | |
David N. Gill(1)(2)(3)
|
| | 67 | | | Director | |
Class II Directors | | | | | | | |
James I. Healy, M.D.(1)
|
| | 57 | | | Director – Chairman of the Board | |
Ashutosh Tyagi, M.D.(3)
|
| | 45 | | | Director | |
Laura J. Hamill(2)(3)
|
| | 57 | | | Director | |
Class III Directors | | | | | | | |
Thomas Gad
|
| | 52 | | | Founder, President, Interim Chief Executive Officer, Head of Business Development and Strategy and Director | |
Johan Wedell-Wedellsborg(1)
|
| | 52 | | | Director | |
| Board Diversity Matrix | |
| Total Number of Directors | |
Gender
|
| |
Female
|
| |
Male
|
| |
Non-Binary
|
| |||||||||
Directors
|
| | | | 1 | | | | | | 6 | | | | | | 0 | | |
Number of Directors Who Identify in Any of the Categories Below: | | | | | | | | | | | | | | | | | | | |
African American or Black
|
| | | | 0 | | | | | | 0 | | | | | | 0 | | |
Alaskan Native or Native American
|
| | | | 0 | | | | | | 0 | | | | | | 0 | | |
Asian
|
| | | | 0 | | | | | | 1 | | | | | | 0 | | |
Hispanic or Latinx
|
| | | | 0 | | | | | | 0 | | | | | | 0 | | |
Native Hawaiian or Pacific Islander
|
| | | | 0 | | | | | | 0 | | | | | | 0 | | |
White
|
| | | | 1 | | | | | | 5 | | | | | | 0 | | |
Two or More Races or Ethnicities
|
| | | | 0 | | | | | | 0 | | | | | | 0 | | |
LGBTQ+
|
| | | | 0 | | | | | | 0 | | | | | | 0 | | |
Name
|
| |
Audit
|
| |
Compensation
|
| |
Nominating and
Corporate Governance |
| |||||||||
Dr. Gérard Ber
|
| | | | | | | | | | X | | | | | | | | |
David N. Gill
|
| | | | X(1) | | | | | | X | | | | | | X | | |
Dr. James I. Healy
|
| | | | X | | | | | | X(1) | | | | | | | | |
Dr. Ashutosh Tyagi
|
| | | | | | | | | | | | | | | | X(1) | | |
Johan Wedell-Wedellsborg
|
| | | | X | | | | | | | | | | | | | | |
Laura J. Hamill
|
| | | | | | | | | | | | | | | | X(2) | | |
Total meetings in fiscal 2021
|
| | | | 4 | | | | | | 1 | | | | | | 1 | | |
Name
|
| |
Age
|
| |
Position
|
|
Thomas Gad | | |
52
|
| | Founder, President, Interim Chief Executive Officer and Head of Business Development and Strategy | |
Bo Kruse | | |
50
|
| | Executive Vice President, Secretary, Treasurer, and Chief Financial Officer | |
Torben Lund-Hansen, Ph.D. | | |
71
|
| | Senior Vice President and Chief Technical Officer | |
Steen Lisby, M.D., DMSc | | |
58
|
| | Senior Vice President and Chief Scientific Officer | |
Joris Wiel Jan Wilms | | |
48
|
| | Senior Vice President and Chief Operating Officer | |
Susan Smith | | |
52
|
| | Senior Vice President and Chief Commercial Officer | |
Vignesh Rajah, M.D. | | |
57
|
| | Senior Vice President and Chief Medical Officer | |
Compensation Element
|
| |
Objective
|
| |
Key Features
|
|
Base Salary (fixed cash) | | | To attract and retain executives. | | | Fixed compensation that is competitive with peer company data and that recognizes each executive’s position, role, responsibility and experience. | |
Annual Performance Bonus (at-risk cash) | | | To motivate and reward the achievement of our short-term strategic and business goals that support our longer term objectives. | | |
Target annual performance bonus opportunities, which are expressed as a percentage of base salary, are reviewed annually.
Actual bonus payments are determined at the end of the year and are dependent upon the actual achievement of specific corporate performance objectives, determined by our Compensation Committee and our Board of Directors.
|
|
Long Term Equity Awards (at-risk equity) | | | To motivate and reward executives for long-term company performance; aligns executives’ interests with stockholder interests and changes in stockholder value. Attracts highly qualified executives and encourages their continued employment over the long-term. | | |
Stock options that are subject to multi-year vesting based on continued service.
Individual awards are determined based on a number of factors, including current corporate and individual performance, outstanding equity holdings and their retention value and total ownership, internal equity among executives and competitive market data.
|
|
| Agios Pharmaceuticals, Inc. | | | Apellis Pharmaceuticals, Inc. | | | Atara Biotherapeutics, Inc. | |
| Blueprint Medicines, Corp. | | | Deciphera Pharmaceuticals, Inc. | | | Esperion Therapeutics, Inc. | |
| G1 Therapeutics, Inc. | | | Global Blood Therapeutics. Inc. | | | Heron Therapeutics, Inc. | |
| Intra-Cellular Therapies, Inc. | | | Iovance Biotherapeutics, Inc. | | | Karyopharm Therapeutics Inc. | |
| MacroGenics, Inc. | | | Reata Pharmaceuticals, Inc. | | | Revance Therapeutics, Inc. | |
| Rhythm Pharmaceuticals, Inc. | | | Rigel Pharmaceuticals, Inc. | | | TG Therapeutics, Inc. | |
| Travere Therapeutics, Inc. | | | Xencor, Inc. | | | Zogenix, Inc. | |
Name and Principal Position
|
| | | | | | | |
Salary
($) |
| |
Bonus
($)(1)(2) |
| |
Non-equity
Incentive Plan Compensation ($)(2)(3) |
| |
Option
Awards ($) |
| |
All Other
Compensation ($)(5) |
| |
Total
($) |
| ||||||||||||||||||
Thomas Gad
Founder, President, Interim Chief Executive Officer and Head of Business Development and Strategy |
| | | | 2021 | | | | | $ | 500,000 | | | | | $ | — | | | | | $ | 187,500 | | | | | $ | 1,095,366 | | | | | $ | 84,835 | | | | | $ | 1,867,701 | | |
| | | 2020 | | | | | $ | 470,800 | | | | | $ | — | | | | | $ | 205,975 | | | | | $ | 2,916,341 | | | | | $ | 84,778 | | | | | $ | 3,677,894 | | | ||
| | | 2019 | | | | | $ | 440,000 | | | | | $ | 242,000 | | | | | $ | — | | | | | $ | 2,295,800(4) | | | | | $ | 84,747 | | | | | $ | 3,062,547 | | | ||
Bo Kruse
Executive Vice President, Secretary, Treasurer and Chief Financial Officer |
| | | | 2021 | | | | | $ | 464,000 | | | | | $ | — | | | | | $ | 174,000 | | | | | $ | 846,396 | | | | | $ | 835 | | | | | $ | 1,485,231 | | |
| | | 2020 | | | | | $ | 420,700 | | | | | $ | — | | | | | $ | 184,056 | | | | | $ | 2,307,242 | | | | | $ | 778 | | | | | $ | 2,912,776 | | | ||
| | | 2019 | | | | | $ | 392,000 | | | | | $ | 215,600 | | | | | $ | — | | | | | $ | 2,295,800(4) | | | | | $ | 747 | | | | | $ | 2,904,147 | | | ||
Dr. Steen Lisby(6)
Senior Vice President and Chief Scientific Officer |
| | | | 2021 | | | | | $ | 327,923 | | | | | $ | — | | | | | $ | 65,585 | | | | | $ | 318,643 | | | | | $ | 477 | | | | | $ | 712,628 | | |
Dr. Vignesh Rajah
Senior Vice President and Chief Medical Officer |
| | | | 2021 | | | | | $ | 314,324 | | | | | $ | — | | | | | $ | 62,865 | | | | | $ | 318,643 | | | | | $ | 29,086 | | | | | $ | 724,918 | | |
| | | 2020 | | | | | $ | 171,453 | | | | | $ | 36,740(7) | | | | | $ | — | | | | | $ | 1,754,600 | | | | | $ | 16,324 | | | | | $ | 1,979,117 | | | ||
| | | 2019 | | | | | $ | — | | | | | $ | — | | | | | $ | — | | | | | $ | — | | | | | $ | — | | | | | $ | — | | | ||
Former Named Executive Officers | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Dr. Claus Juan Møller-San Pedro M.D., Ph.D.
Former Chief Executive Officer(8) |
| | | | 2021 | | | | | $ | 630,000 | | | | | $ | — | | | | | $ | 283,500 | | | | | $ | 2,290,248 | | | | | $ | 84,835 | | | | | $ | 3,288,583 | | |
| | | 2020 | | | | | $ | 574,000 | | | | | $ | — | | | | | $ | 301,350 | | | | | $ | 7,232,652 | | | | | $ | 84,778 | | | | | $ | 8,192,780 | | | ||
| | | 2019 | | | | | $ | 550,000 | | | | | $ | 332,750 | | | | | $ | — | | | | | $ | 4,856,500(4) | | | | | $ | 84,747 | | | | | $ | 5,823,997 | | | ||
Philip Herman(9)
Former Senior Vice President and Chief Commercial Officer |
| | | | 2020 | | | | | $ | 403,920 | | | | | $ | 141,372 | | | | | $ | — | | | | | $ | 1,196,200 | | | | | $ | 444 | | | | | $ | 1,741,936 | | |
| | | 2019 | | | | | $ | 367,200 | | | | | $ | 128,520 | | | | | $ | — | | | | | $ | 640,200 | | | | | $ | 420 | | | | | $ | 1,136,340 | | |
Name
|
| |
Award Type
|
| |
Grant Date(1)
|
| |
Non-equity
Incentive Target ($)(2) |
| |
Stock Option
Awards:Number of Securities Underlying Options (#) |
| |
Exercise
Price of Stock Option Awards ($/share) |
| |
Grant Date
Fair Value of Stock Option Awards ($)(3) |
| ||||||||||||
Thomas Gad | | | Stock Option | | |
December 14, 2021
|
| | | | | | | | | | 110,000 | | | | | $ | 15.73 | | | | | $ | 1,095,366 | | |
| | |
Performance Bonus
|
| | | | | | $ | 250,000 | | | | | | — | | | | | | | | | | | | | | |
Bo Kruse
|
| |
Stock Option
|
| |
December 14, 2021
|
| | | | | | | | | | 85,000 | | | | | $ | 15.73 | | | | | $ | 846,396 | | |
|
Performance Bonus
|
| | | | | | $ | 232,000 | | | | | | | | | | | | | | | | | | | | | ||
Dr. Steen Lisby
|
| |
Stock Option
|
| |
December 14, 2021
|
| | | | | | | | | | 32,000 | | | | | $ | 15.73 | | | | | $ | 318,643 | | |
|
Performance Bonus
|
| | | | | | $ | 81,981 | | | | | | | | | | | | | | | | | | | | | ||
Dr. Vignesh Rajah
|
| |
Stock Option
|
| |
December 14, 2021
|
| | | | | | | | | | 32,000 | | | | | $ | 15.73 | | | | | $ | 318,643 | | |
|
Performance Bonus
|
| | | | | | $ | 78,581 | | | | | | | | | | | | | | | | | | | | | ||
Former Named Executive Officer | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Dr. Claus Juan Møller-San Pedro
M.D., Ph.D. |
| |
Stock Option
|
| |
December 14, 2021
|
| | | | | | | | | | 230,000 | | | | | $ | 15.73 | | | | | $ | 2,290,248 | | |
|
Performance Bonus
|
| | | | | | $ | 378,000 | | | | | | | | | | | | | | | | | | | | |
| | |
Option Awards
|
| ||||||||||||||||||
| | |
Number of Securities
Underlying Unexercised Options |
| |
Option
Exercise Price ($/Sh) |
| |
Option
Expiration Date |
| ||||||||||||
Name
|
| |
Exercisable(#)
|
| |
Unexercisable(#)
|
| |||||||||||||||
Thomas Gad(1)
|
| | | | 169,000 | | | | | | — | | | | | $ | 2.00 | | | |
June 10, 2025
|
|
| | | | | 166,000 | | | | | | — | | | | | $ | 4.38 | | | |
October 21, 2026
|
|
| | | | | 16,000 | | | | | | — | | | | | $ | 8.50 | | | |
December 14, 2026
|
|
| | | | | 91,667 | | | | | | 8,333 | | | | | $ | 11.16 | | | |
April 24, 2028
|
|
| | | | | 80,625 | | | | | | 26,875 | | | | | $ | 21.97 | | | |
December 11, 2028
|
|
| | | | | 62,292 | | | | | | 67,708 | | | | | $ | 30.34 | | | |
January 7, 2030
|
|
| | | | | 22,863 | | | | | | 68,588 | | | | | $ | 53.88 | | | |
December 15, 2030
|
|
| | | | | — | | | | | | 110,000 | | | | | $ | 15.73 | | | |
December 14, 2031
|
|
Bo Kruse(2)
|
| | | | 300,000 | | | | | | — | | | | | $ | 2.00 | | | |
June 10, 2025
|
|
| | | | | 133,000 | | | | | | — | | | | | $ | 4.38 | | | |
October 21, 2026
|
|
| | | | | 14,000 | | | | | | — | | | | | $ | 8.50 | | | |
December 14, 2026
|
|
| | | | | 68,750 | | | | | | 6,250 | | | | | $ | 11.16 | | | |
April 24, 2028
|
|
| | | | | 80,625 | | | | | | 26,875 | | | | | $ | 21.97 | | | |
December 11, 2028
|
|
| | | | | 62,292 | | | | | | 67,708 | | | | | $ | 30.34 | | | |
January 7, 2030
|
|
| | | | | 18,088 | | | | | | 54,263 | | | | | $ | 53.88 | | | |
December 15, 2030
|
|
| | | | | — | | | | | | 85,000 | | | | | $ | 15.73 | | | |
December 14, 2031
|
|
Dr. Steen Lisby(3)
|
| | | | 40,000 | | | | | | — | | | | | $ | 9.35 | | | |
September 13, 2027
|
|
| | | | | 15,000 | | | | | | 5,000 | | | | | $ | 21.97 | | | |
December 11, 2028
|
|
| | | | | 10,000 | | | | | | 10,000 | | | | | $ | 33.74 | | | |
December 10, 2029
|
|
| | | | | 5,000 | | | | | | 15,000 | | | | | $ | 53.88 | | | |
December 15, 2030
|
|
| | | | | — | | | | | | 32,000 | | | | | $ | 15.73 | | | |
December 14, 2031
|
|
Dr. Vignesh Rajah(4)
|
| | | | 15,000 | | | | | | 25,000 | | | | | $ | 48.67 | | | |
June 23, 2030
|
|
| | | | | 5,000 | | | | | | 15,000 | | | | | $ | 53.88 | | | |
December 15, 2030
|
|
| | | | | — | | | | | | 32,000 | | | | | $ | 15.73 | | | |
December 14, 2031
|
|
Former Named Executive Officers | | | | | | | | | | | | | | | | | | | | | | |
Dr. Claus Juan Møller-San Pedro(5)
|
| | | | 500,000 | | | | | | — | | | | | $ | 2.00 | | | |
June 10, 2025
|
|
| | | | | 200,000 | | | | | | — | | | | | $ | 4.38 | | | |
October 21, 2026
|
|
| | | | | 18,000 | | | | | | — | | | | | $ | 8.50 | | | |
December 14, 2026
|
|
| | | | | 114,583 | | | | | | 10,417 | | | | | $ | 11.16 | | | |
April 24, 2028
|
|
| | | | | 158,625 | | | | | | 52,875 | | | | | $ | 21.97 | | | |
December 11, 2028
|
|
| | | | | 131,771 | | | | | | 143,229 | | | | | $ | 30.34 | | | |
January 7, 2030
|
|
| | | | | 56,700 | | | | | | 170,100 | | | | | $ | 53.88 | | | |
December 15, 2030
|
|
| | | | | — | | | | | | 230,000 | | | | | $ | 15.73 | | | |
December 14, 2031
|
|
| | |
Option Awards
|
| ||||||||||||||||||
| | |
Number of Securities
Underlying Unexercised Options |
| |
Option
Exercise Price ($/Sh) |
| |
Option
Expiration Date |
| ||||||||||||
Name
|
| |
Exercisable(#)
|
| |
Unexercisable(#)
|
| |||||||||||||||
Philip Herman(6)
Former Senior Vice President and Chief Commercial Officer |
| | | | 17,083 | | | | | | — | | | | | $ | 13.11 | | | |
July 10, 2028
|
|
| | | 12,500 | | | | | | — | | | | | $ | 21.45 | | | |
June 12, 2029
|
| ||
| | | | | 10,000 | | | | | | — | | | | | $ | 33.74 | | | |
December 10, 2029
|
|
| | | | | 7,500 | | | | | | — | | | | | $ | 48.67 | | | |
June 23, 2030
|
|
| | | | | 5,000 | | | | | | — | | | | | $ | 53.88 | | | |
December 15, 2030
|
|
Name
|
| |
Number of Shares
Acquired on Exercise (#) |
| |
Value Realized
on Exercise ($)(1) |
| ||||||
Thomas Gad
|
| | | | 167,000 | | | | | | 4,688,354 | | |
Executive benefits and payment upon termination
|
| |
Voluntary
resignation not for good reason ($) |
| |
Voluntary
resignation for good reason ($) |
| |
Termination
by Company without cause ($) |
| |
Termination
by Company for cause ($) |
| |
Upon a
change of control event ($) |
| |
Termination by
Company without cause or voluntary resignation for good reason within 12 months following a change of control ($) |
| ||||||||||||||||||
Thomas Gad | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Compensation: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Base salary
|
| | | $ | — | | | | | $ | 1,000,000 | | | | | $ | 1,000,000 | | | | | $ | — | | | | | $ | — | | | | | $ | 1,000,000 | | |
Cash incentive bonus
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Equity awards unvested and accelerated
|
| | | | —(1) | | | | | | —(2) | | | | | | —(2) | | | | | | —(1) | | | | | | 94,833(3) | | | | | | — | | |
Benefits and Perquisites: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Health care continuation
|
| | | | — | | | | | | 73,392 | | | | | | 73,392 | | | | | | — | | | | | | — | | | | | | 73,392 | | |
Housing allowance
|
| | | | — | | | | | | 168,000 | | | | | | 168,000 | | | | | | — | | | | | | — | | | | | | 168,000 | | |
Total
|
| | | $ | — | | | | | $ | 1,241,392 | | | | | $ | 1,241,392 | | | | | $ | — | | | | | $ | 94,833 | | | | | $ | 1,241,392 | | |
Bo Kruse | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Compensation: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Base salary
|
| | | $ | — | | | | | $ | 928,000 | | | | | $ | 928,000 | | | | | $ | — | | | | | $ | — | | | | | $ | 928,000 | | |
Cash incentive bonus
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Equity awards unvested and accelerated
|
| | | | —(1) | | | | | | —(2) | | | | | | —(2) | | | | | | —(1) | | | | | | 72,363(3) | | | | | | — | | |
Benefits and Perquisites: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Health care continuation
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Housing allowance
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Total
|
| | | $ | — | | | | | $ | 928,000 | | | | | $ | 928,000 | | | | | $ | — | | | | | $ | 72,363 | | | | | $ | 928,000 | | |
Dr. Steen Lisby | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Compensation: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Base salary
|
| | | $ | — | | | | | $ | 327,923 | | | | | $ | 327,923 | | | | | $ | — | | | | | $ | — | | | | | $ | 327,923 | | |
Cash incentive bonus
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 81,981 | | |
Equity awards unvested and accelerated
|
| | | | —(1) | | | | | | —(2) | | | | | | —(2) | | | | | | —(1) | | | | | | 15,360(3) | | | | | | — | | |
Benefits and Perquisites: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Health care continuation
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 18,565 | | |
Housing allowance
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Total
|
| | | $ | — | | | | | $ | 327,923 | | | | | $ | 327,923 | | | | | $ | — | | | | | $ | 15,360 | | | | | $ | 428,469 | | |
Dr. Vignesh Rajah | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Compensation: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Base salary
|
| | | $ | — | | | | | $ | 314,324 | | | | | $ | 314,324 | | | | | $ | — | | | | | $ | — | | | | | $ | 314,324 | | |
Cash incentive bonus
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 78,581 | | |
Equity awards unvested and accelerated
|
| | | | —(1) | | | | | | —(2) | | | | | | —(2) | | | | | | —(1) | | | | | | 15,360(3) | | | | | | — | | |
Benefits and Perquisites: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Health care continuation
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Housing allowance
|
| | | | — | | | | | | 29,717 | | | | | | 29,717 | | | | | | — | | | | | | — | | | | | | — | | |
Total
|
| | | $ | 0 | | | | | $ | 344,041 | | | | | $ | 344,041 | | | | | $ | — | | | | | $ | 15,360 | | | | | $ | 392,905 | | |
|
Chief Executive Officer 2021 Annual Total Compensation
|
| | | $ | 3,288,583 | | |
|
Median Employee 2021 Annual Total Compensation
|
| | | $ | 189,325 | | |
|
Ratio of CEO to Median Employee Compensation
|
| | | | 17.4 | | |
Position
|
| |
Retainer
|
| |||
Board Member
|
| | | $ | 40,000 | | |
Audit Committee Chair
|
| | | $ | 20,000 | | |
Compensation Committee Chair
|
| | | $ | 15,000 | | |
Nominating and Corporate Governance Committee Chair
|
| | | $ | 10,000 | | |
Audit Committee Member
|
| | | $ | 10,000 | | |
Compensation Committee Member
|
| | | $ | 7,500 | | |
Nominating and Corporate Governance Committee Member
|
| | | $ | 5,000 | | |
Name
|
| |
Fees Earned or
Paid in Cash ($) |
| |
Option
Awards ($)(1) |
| |
Total ($)
|
| |||||||||
Johan Wedell-Wedellsborg
|
| | | $ | 50,000 | | | | | $ | 387,024 | | | | | $ | 437,024 | | |
Dr. Gérard Ber
|
| | | $ | 50,462 | | | | | $ | 387,024 | | | | | $ | 437,486 | | |
Dr. Ashutosh Tyagi
|
| | | $ | 50,000 | | | | | $ | 387,024 | | | | | $ | 437,024 | | |
Dr. James I. Healy
|
| | | $ | 65,000 | | | | | $ | 387,024 | | | | | $ | 452,024 | | |
David N. Gill
|
| | | $ | 72,500 | | | | | $ | 387,024 | | | | | $ | 459,524 | | |
Laura J. Hamill
|
| | | $ | 42,038 | | | | | $ | 387,024 | | | | | $ | 429,062 | | |
| | |
Option Awards
|
| ||||||||||||||||||
| | |
Number of Securities
Underlying Unexercised Options |
| |
Option
Exercise Price ($/Sh) |
| |
Option
Expiration Date |
| ||||||||||||
Name
|
| |
Exercisable(#)
|
| |
Unexercisable(#)
|
| |||||||||||||||
Johan Wedell-Wedellsborg
|
| | | | 36,000 | | | | | | — | | | | | $ | 4.38 | | | |
October 21, 2026(1)
|
|
| | | | | 32,000 | | | | | | — | | | | | $ | 11.16 | | | |
April 24, 2028(2)
|
|
| | | | | 16,000 | | | | | | — | | | | | $ | 21.45 | | | |
June 12, 2029(3)
|
|
| | | | | 16,000 | | | | | | — | | | | | $ | 48.67 | | | |
June 24, 2030(3)
|
|
| | | | | 8,000 | | | | | | 8,000 | | | | | $ | 37.53 | | | |
June 10, 2031(3)
|
|
Dr. Gérard Ber
|
| | | | 32,000 | | | | | | — | | | | | $ | 21.97 | | | |
December 12, 2028(2)
|
|
| | | | | 16,000 | | | | | | — | | | | | $ | 21.45 | | | |
June 12, 2029(3)
|
|
| | | | | 16,000 | | | | | | — | | | | | $ | 48.67 | | | |
June 23, 2030(3)
|
|
| | | | | 8,000 | | | | | | 8,000 | | | | | $ | 37.53 | | | |
June 10, 2031(3)
|
|
Dr. Ashutosh Tyagi
|
| | | | 16,000 | | | | | | — | | | | | $ | 21.45 | | | |
June 12, 2029(3)
|
|
| | | | | 16,000 | | | | | | 16,000 | | | | | | 48.67 | | | |
June 23, 2030(2)
|
|
| | | | | 16,000 | | | | | | — | | | | | $ | 48.67 | | | |
June 23, 2030(3)
|
|
| | | | | 8,000 | | | | | | 8,000 | | | | | $ | 37.53 | | | |
June 10, 2031(3)
|
|
| | |
Option Awards
|
| ||||||||||||||||||
| | |
Number of Securities
Underlying Unexercised Options |
| |
Option
Exercise Price ($/Sh) |
| |
Option
Expiration Date |
| ||||||||||||
Name
|
| |
Exercisable(#)
|
| |
Unexercisable(#)
|
| |||||||||||||||
Dr. James I. Healy
|
| | | | 14,222 | | | | | | — | | | | | $ | 11.16 | | | |
April 24, 2028(2)
|
|
| | | | | 8,000 | | | | | | — | | | | | $ | 21.45 | | | |
June 12, 2029(3)
|
|
| | | | | 16,000 | | | | | | — | | | | | $ | 48.67 | | | |
June 23, 2030(3)
|
|
| | | | | 8,000 | | | | | | 8,000 | | | | | $ | 37.53 | | | |
June 10, 2031(3)
|
|
David N. Gill
|
| | | | 24,000 | | | | | | — | | | | | $ | 11.16 | | | |
April 24, 2028(2)
|
|
| | | | | 16,000 | | | | | | — | | | | | $ | 21.45 | | | |
June 12, 2029(3)
|
|
| | | | | 16,000 | | | | | | — | | | | | $ | 48.67 | | | |
June 23, 2030(3)
|
|
| | | | | 8,000 | | | | | | 8,000 | | | | | $ | 37.53 | | | |
June 10, 2031(3)
|
|
Laura J. Hamill
|
| | | | 16,000 | | | | | | 16,000 | | | | | $ | 48.67 | | | |
June 23, 2030(2)
|
|
| | | | | 8,000 | | | | | | 8,000 | | | | | $ | 37.53 | | | |
June 10, 2031(3)
|
|
Plan Category
|
| |
Number of securities
to be issued upon exercise of outstanding options, warrants and rights |
| |
Weighted average
exercise price of outstanding options, warrants and rights |
| |
Number of securities
remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) |
| |||||||||
| | |
(a)
|
| |
(b)
|
| |
(c)
|
| |||||||||
Equity compensation plans approved by security holders
|
| | | | 6,716,035(1) | | | | | $ | 22.43(2) | | | | | | 3,638,576(3) | | |
Equity compensation plans not approved by security
holders |
| | | | — | | | | | | — | | | | | | — | | |
Total
|
| | | | 6,716,035 | | | | | $ | 22.43 | | | | | | 3,638,576(4) | | |
Fee Category
|
| |
2021
|
| |
2020
|
| ||||||
Audit Fees(1)
|
| | | $ | 955,000 | | | | | $ | 909,000 | | |
Audit-Related Fees(2)
|
| | | $ | 22,000 | | | | | | — | | |
Tax Fees(3)
|
| | | $ | 49,460 | | | | | | 2,100 | | |
All Other Fees(4)
|
| | | $ | 6,650 | | | | | | 2,700 | | |
Total Fees
|
| | | $ | 1,033,110 | | | | | $ | 913,800 | | |
Name and Address of Beneficial Owner
|
| |
Number of
Shares Beneficially Owned |
| |
Percentage
of Shares Beneficially Owned |
| ||||||
5% Stockholders | | | | | | | | | | | | | |
WG Biotech ApS(1)
|
| | | | 4,178,465 | | | | | | 9.56% | | |
Rungsted Strandvej 113
|
| | | | | | | | | | | | |
DK 2960
|
| | | | | | | | | | | | |
Rungsted Kyst, Denmark
|
| | | | | | | | | | | | |
Attn: Johan Wedell-Wedellsborg
|
| | | | | | | | | | | | |
HBM Healthcare Investments (Cayman) Limited(2)
|
| | | | 3,090,954 | | | | | | 7.07% | | |
Governors Square
|
| | | | | | | | | | | | |
23 Lime Tree Bay Avenue
|
| | | | | | | | | | | | |
PO Box 30852
|
| | | | | | | | | | | | |
Grand Cayman, Cayman Islands
|
| | | | | | | | | | | | |
BlackRock, Inc(3)
|
| | | | 2,767,360 | | | | | | 6.33% | | |
55 East 52nd Street
|
| | | | | | | | | | | | |
New York, NY 10055
|
| | | | | | | | | | | | |
Sofinnova Venture Partners X, L.P.(4)
|
| | | | 2,194,278 | | | | | | 5.02% | | |
3000 Sand Hill Road
|
| | | | | | | | | | | | |
Building 4-Suite 250
|
| | | | | | | | | | | | |
Menlo Park, CA 94025
|
| | | | | | | | | | | | |
Attn: Hooman Shahlavi, Partner & General Counsel
|
| | | | | | | | | | | | |
Name and Address of Beneficial Owner
|
| |
Number of
Shares Beneficially Owned |
| |
Percentage
of Shares Beneficially Owned |
| ||||||
Named Executive Officers and Directors | | | | | | | | | | | | | |
Thomas Gad(5)
|
| | | | 1,326,077 | | | | | | 2.81% | | |
Bo Kruse(6)
|
| | | | 896,357 | | | | | | 1.90% | | |
Dr. Steen Lisby
|
| | | | 76,250 | | | | | | * | | |
Dr. Vignesh Rajah(7)
|
| | | | 29,321 | | | | | | * | | |
Johan Wedell-Wedellsborg(8)
|
| | | | 4,293,132 | | | | | | 9.11% | | |
Laura Hamill
|
| | | | 35,111 | | | | | | * | | |
Dr. Gérard Ber
|
| | | | 78,667 | | | | | | * | | |
Dr. James I. Healy(9)
|
| | | | 2,272,945 | | | | | | 4.82% | | |
Dr. Ashutosh Tyagi
|
| | | | 67,111 | | | | | | * | | |
David N. Gill
|
| | | | 70,667 | | | | | | * | | |
All Current Executive Officers and Directors as a Group
(13 persons)(10) |
| | | | 9,453,800 | | | | | | 20.61% | | |